Stock Financial Ratios, Dividends, Split History

MUX / McEwen Mining Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)701.07
Enterprise Value ($M)673.92
Book Value ($M)514.62
Book Value / Share1.53
Price / Book1.34
NCAV ($M)6.10
NCAV / Share0.02
Price / NCAV119.97
Share Statistics
Common Stock Shares Outstanding 337,051,000
Weighted Average Number Of Shares Outstanding Basic 313,887,000
Weighted Average Number Of Diluted Shares Outstanding 313,887,000
Common Shares Outstanding 337,054,594
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.02
Return on Equity (ROE)-0.02
Balance Sheet (mrq) ($M)
Quick Ratio1.25
Current Ratio1.97
Income Statement (mra) ($M)
Revenue Mineral Sales67,465,000.00
Equity Method Investment Summarized Financial Information Revenue0.00
Operating Income-26.03
Net Income-10.63
Earnings Per Share Basic-0.03
Earnings Per Share Diluted-0.03
Cash Flow Statement (mra) ($M)
Cash From Operations-15.43
Cash from Investing-34.47
Cash from Financing-34.47
Identifiers and Descriptors
Central Index Key (CIK)314203
Related CUSIPS
58039P907 58039P957

Split History

Stock splits are used by McEwen Mining Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

20h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Timberline Resources Announces Gold and Copper Assay Results for the Elder Creek Project, Battle Mountain District, Nevada

13h accesswire
COEUR D'ALENE, ID / ACCESSWIRE / June 18, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that geologic mapping, surface sampling, and an aeromagnetic survey have defined a large porphyry copper target on the Elder Creek project in the Battle Mountain District of Nevada. Timberline has entered into a purchase and sale agreement with America's Gold Exploration Inc. (43-0)

U.S. Allowing China And Russia To Accumulate Gold On The Cheap

2018-06-12 seekingalpha
U.S. suppression of paper gold price allows China and Russia to accumulate physical gold reserves at a discount. (8-0)

McEwen Believes Gold Bull Market Is Underway As Nevada Gold Bar Mine Prepares To Open

2018-06-04 seekingalpha
Rob McEwen made a persuasive case in his May 31st AGM presentation that a gold bull market began in 2016 and is advancing in stealth silence. Gold price was at about $1,040 per ounce in early 2016 and has risen to $1,300 today. (15-0)

10 Best Risk/Reward Leveraged Gold Stocks

2018-06-01 seekingalpha
Below is a list of 10 quality gold producers. I have selected them as the best risk/reward leveraged gold stocks. All of these should outperform the price of gold if it rises. In fact, I expect all of these stocks to double in value if gold reaches $1,600. These are the stocks that you want to own if you are looking for high returns if gold prices start trending. Also, if you are looking for a way to hedge against a market crash, then these stocks offer a potential hedge. (37-1)

Mining companies still reluctant to tap Argentina deposits

2018-05-23 reuters
BUENOS AIRES (Reuters) - Despite Argentine President Mauricio Macri’s pro-business policies, international mining companies are still reluctant to invest in Argentina amid a lack of regulatory clarity. (18-0)

CUSIP: 58039P107